Several brokerages have updated their recommendations and price targets on shares of AstraZeneca (LON: AZN) in the last few weeks:

  • 12/5/2017 – AstraZeneca had its price target raised by analysts at Deutsche Bank AG from GBX 5,600 ($75.37) to GBX 5,700 ($76.72). They now have a “buy” rating on the stock.
  • 12/4/2017 – AstraZeneca had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 12/1/2017 – AstraZeneca had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a GBX 5,000 ($67.29) price target on the stock.
  • 11/30/2017 – AstraZeneca was given a new GBX 4,800 ($64.60) price target on by analysts at J P Morgan Chase & Co. They now have a “neutral” rating on the stock.
  • 11/16/2017 – AstraZeneca had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a GBX 5,100 ($68.64) price target on the stock.
  • 11/16/2017 – AstraZeneca had its price target raised by analysts at HSBC Holdings PLC from GBX 4,340 ($58.41) to GBX 4,380 ($58.95). They now have a “reduce” rating on the stock.
  • 11/10/2017 – AstraZeneca was given a new GBX 5,000 ($67.29) price target on by analysts at Morgan Stanley. They now have a “neutral” rating on the stock.
  • 11/10/2017 – AstraZeneca was given a new GBX 5,000 ($67.29) price target on by analysts at S&P Global. They now have a “neutral” rating on the stock.
  • 11/10/2017 – AstraZeneca had its “buy” rating reaffirmed by analysts at Kepler Capital Markets. They now have a GBX 5,250 ($70.66) price target on the stock.
  • 11/10/2017 – AstraZeneca had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 11/10/2017 – AstraZeneca had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 5,600 ($75.37) price target on the stock.
  • 11/9/2017 – AstraZeneca was given a new GBX 4,550 ($61.24) price target on by analysts at UBS AG. They now have a “neutral” rating on the stock.
  • 11/9/2017 – AstraZeneca had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 11/8/2017 – AstraZeneca had its “buy” rating reaffirmed by analysts at Citigroup Inc..
  • 11/6/2017 – AstraZeneca had its price target raised by analysts at Investec from GBX 4,900 ($65.95) to GBX 5,500 ($74.02). They now have a “buy” rating on the stock.
  • 11/6/2017 – AstraZeneca had its “buy” rating reaffirmed by analysts at Investec. They now have a GBX 5,500 ($74.02) price target on the stock, up previously from GBX 4,900 ($65.95).
  • 11/6/2017 – AstraZeneca had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a GBX 5,100 ($68.64) price target on the stock.
  • 11/2/2017 – AstraZeneca was given a new GBX 3,800 ($51.14) price target on by analysts at Goldman Sachs Group Inc. They now have a “sell” rating on the stock.
  • 11/1/2017 – AstraZeneca had its “buy” rating reaffirmed by analysts at Berenberg Bank. They now have a GBX 5,800 ($78.06) price target on the stock.
  • 11/1/2017 – AstraZeneca had its price target raised by analysts at from GBX 4,150 ($55.85) to GBX 4,340 ($58.41). They now have a “reduce” rating on the stock.
  • 11/1/2017 – AstraZeneca had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 5,600 ($75.37) price target on the stock.
  • 11/1/2017 – AstraZeneca had its price target raised by analysts at Kepler Capital Markets from GBX 5,200 ($69.99) to GBX 5,250 ($70.66). They now have a “buy” rating on the stock.
  • 11/1/2017 – AstraZeneca had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 11/1/2017 – AstraZeneca had its “hold” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 5,000 ($67.29) price target on the stock.
  • 10/31/2017 – AstraZeneca had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 10/23/2017 – AstraZeneca was given a new GBX 4,550 ($61.24) price target on by analysts at UBS AG. They now have a “neutral” rating on the stock.
  • 10/23/2017 – AstraZeneca had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 10/20/2017 – AstraZeneca was given a new GBX 4,700 ($63.26) price target on by analysts at Morgan Stanley. They now have a “neutral” rating on the stock.
  • 10/18/2017 – AstraZeneca was given a new GBX 4,500 ($60.57) price target on by analysts at J P Morgan Chase & Co. They now have a “neutral” rating on the stock.
  • 10/17/2017 – AstraZeneca had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 10/17/2017 – AstraZeneca had its “sell” rating reaffirmed by analysts at Goldman Sachs Group Inc. They now have a GBX 3,800 ($51.14) price target on the stock.
  • 10/16/2017 – AstraZeneca was upgraded by analysts at Credit Suisse Group AG from a “neutral” rating to an “outperform” rating. They now have a GBX 5,800 ($78.06) price target on the stock, up previously from GBX 4,800 ($64.60).
  • 10/16/2017 – AstraZeneca had its price target raised by analysts at Jefferies Group LLC from GBX 4,900 ($65.95) to GBX 5,100 ($68.64). They now have a “hold” rating on the stock.
  • 10/11/2017 – AstraZeneca had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 5,600 ($75.37) price target on the stock.
  • 10/9/2017 – AstraZeneca was given a new GBX 4,550 ($61.24) price target on by analysts at UBS AG. They now have a “neutral” rating on the stock.
  • 10/9/2017 – AstraZeneca had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 10/9/2017 – AstraZeneca had its price target raised by analysts at from GBX 4,100 ($55.18) to GBX 4,150 ($55.85). They now have a “reduce” rating on the stock.

AstraZeneca PLC (AZN) traded down GBX 19.50 ($0.26) on Thursday, reaching GBX 4,704 ($63.31). The company’s stock had a trading volume of 397,216 shares, compared to its average volume of 2,170,000. AstraZeneca PLC has a 12-month low of GBX 3,996 ($53.78) and a 12-month high of GBX 5,520 ($74.29).

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Ratings for AstraZeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.